If I’d invested £5k in GSK shares one year ago here’s what I’d have today

GSK shares have disappointed lately, but today’s low valuation and rising yield could make now the perfect time to buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Young Black woman looking concerned while in front of her laptop

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE: GSK) shares haven’t done much since it spun off its consumer healthcare business Haleon last July. I see this as an opportunity to buy the FTSE 100 pharmaceutical stock at an attractive price, then hold on for the recovery.

In its halcyon days as GlaxoSmithKline, this was arguably the most popular dividend stock on the entire index, reliably yielding 5% or 6% a year. It lost that mantle as CEO Emma Walmsley froze the dividend at 80p for years, diverting the company’s cash into R&D rather than shareholders’ pockets. The Glaxo share price drifted lower, and income investors drifted away.

I’m after income and growth

GSK reported a positive 2022 with sales up 19% to £29.3bn, while generating free cash flow of £3.3bn. Last month’s Q1 profits and revenues also beat expectations at £7bn and £2.1bn respectively, boosted by successful shingles and meningitis treatments.

Should you invest £1,000 in Sainsbury's right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Sainsbury's made the list?

See the 6 stocks

Yet the share price remains sluggish. It’s up just 2.16% over the last three months. Over one year, it’s down 16.12% to 1,475p per share. That compares to growth of 4.17% across the FTSE 100 as a whole.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

If I had invested £5,000 in GSK shares one year ago, as I was tempted to do, I would have just £4,194 today, a loss of £806.

In practice, I would have slightly more, thanks to the dividend. A year ago, £5k would have bought around 272 shares at 1,839p each. The 2022 dividend of 44p per share would be worth around £120, lifting my stake to £4,314. I’d still be down £686 though.

So what does the future hold and should I invest £5,000 in GSK today?

Walmsley has been holding out the promise of a steadily flowing drugs pipeline for some years now, but there are signs she will finally deliver. At last count, the firm had 69 vaccines and speciality medicines in various states of progress.

Getting drugs approved is a long and uncertain process, and no doubt there will be plenty of slips and setbacks along the way. If the pipeline doesn’t flow as hoped, the GSK share price may continue to underwhelm.

I’m in it for the long term

As a private investor, it’s impossible for me to have a clear view of GSK’s chances of success, but I have one thing in my favour. Time.

I would only buy a stock like this with a five- or 10-year view, which should give plenty of scope for its raft of treatments to build.

In the interim, there’s the dividend. Currently, the yield is disappointing at 3%, below the FTSE 100 average of 3.5%. Yet it’s covered 3.2 times by earnings, giving scope for progression. Better still, it’s forecast to hit 3.8% this year, and should still be covered 2.6 times. With luck, it should climb higher over time, although, as ever with dividends, there are no guarantees.

GSK’s operating margins are forecast to climb from 21.9% to 28.5%, while management predicts adjusted operating profit will rise between 10% and 12%.

I don’t directly hold any pharmaceutical stocks, and would like to change that. Today’s low valuation of 10.5 times earnings looks like a good entry point. Hopefully, GSK will begin to deliver more growth and income than it did over the last 12 months.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Sainsbury's right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Sainsbury's made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, £5,000 invested in Tesla stock could be worth…

Tesla stock has endured a miserable year so far, falling by 29%. Muhammad Cheema takes a look at how it…

Read more »

Investing Articles

See what £10,000 invested in Tesla shares at their mid-December peak is worth today 

As the world absorbs the full scale of Donald Trump's tariffs, Tesla shares are reeling. Investors who bought the stock…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Dividend Shares

2 ‘safe’ LSE dividend stocks to consider as global markets sell off

As global markets experience high levels of volatility due to economic uncertainty, investors are piling into these ‘safe-haven’ dividend stocks.

Read more »

Investing Articles

US stock market rout: an unmissable opportunity for investors?

His tech-heavy portfolio has been smashed by Trump’s tariffs. However, Dr James Fox believes there could be some opportunities in…

Read more »

Investing Articles

After a 13% ‘Trump tariff’ fall, is the Barclays share price too cheap to miss?

Does the Barclays share price fall mean we should all panic and run screaming from the stock market? Nah, of…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

2 investment trusts to consider for a Stocks and Shares ISA

These two investment trusts have a different focus -- but our writer sees both as worth considering, one more for…

Read more »

Investing Articles

Deutsche Bank reiterates Buy rating on 9.6% yielding FTSE 250 stock that was “most shorted in UK”

Our writer investigates why a major broker remains optimistic about a FTSE 250 stock that was once the most shorted…

Read more »

Investing Articles

2 things to remember when stock markets are turbulent

US trade policy has rattled the stock markets in New York, London and elsewhere. Our writer outlines a couple of…

Read more »